Drug intelligence / Profile preview

DAL K29

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DAL K29 is a monoclonal antibody (MAB) developed to target human renal cell carcinoma (RCC). It has been investigated for its ability to localize specifically in tumor tissue in xenograft models. Studies have also explored the localization and clearance rates of its F(ab)2 fragments compared to the parent MAB.

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on DAL K29.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DAL K29.

Explore the full profile